Studienzentrum Dr Med Schlenska

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• COPD5 trials
• Asthma2 trials

Phase

• Phase 34 trials
• Phase 23 trials

Status

• Completed7 trials

Lead sponsor

• Chiesi Farmaceutici S.p.A.2 trials
• Genentech Inc.1 trial
• Genentech, Inc.1 trial
• HAL Allergy1 trial
• Sanofi1 trial
• and 1 more

Closed trials

• Completed

  A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma

  NCT06664619· Phase 3· Teva Branded Pharmaceutical Products R&D LLC· Source

• Completed

  A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM)

  NCT06920771· Phase 3· HAL Allergy· Source

• Completed

  Mechanistic Study of the Effect of Itepekimab on Airway Inflammation in Patients With COPD

  NCT05326412· Phase 2· Sanofi· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Astegolimab in Patients With Chronic Obstructive Pulmonary Disease (COPD)

  2023-507093-40-00· Phase 2· Genentech Inc.· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

  NCT05037929· Phase 2· Genentech, Inc.· Source

• Completed

  The efficacy and safety of two doses of CHF6001 DPI as add-on to maintenance COPD triple therapy

  NCT04636814· Phase 3· Chiesi Farmaceutici S.p.A.· Source

• Completed

  The efficacy and the safety of two doses of CHF6001 for the treatment of Chronic Obstructive Pulmonary Disease (COPD)

  NCT04636801· Phase 3· Chiesi Farmaceutici S.p.A.· Source